Page 268 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 14 Cancer Immunotherapy 247

160. Gentschev I, Adelfinger M, Josupeit R, et al.: Preclinical evaluation 179. Chuang TF, Lee SC, Liao KW, et al.: Electroporation-mediated
of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma, IL-12 gene therapy in a transplantable canine cancer model, Int J
PLoS One 7(5):e37239, 2012. Cancer 125(3):698–707, 2009.
VetBooks.ir 161. Patil SS, Gentschev I, Adelfinger M, et al.: Virotherapy of canine 180. Pavlin D, Cemazar M, Cor A, et al.: Electrogene therapy with
tumors with oncolytic vaccinia virus GLV-1h109 expressing an
interleukin-12 in canine mast cell tumors, Radiol Oncol 45(1):31–
39, 2011.
anti-VEGF single-chain antibody, PLoS One 7(10):e47472,
2012. 181. Cicchelero L, Denies S, Haers H, et al.: Intratumoural interleu-
162. Adelfinger M, Bessler S, Frentzen A, et al.: Preclinical testing onco- kin 12 gene therapy stimulates the immune system and decreases
lytic vaccinia virus strain GLV-5b451 expressing an anti-VEGF angiogenesis in dogs with spontaneous cancer, Vet Comp Oncol
single-chain antibody for canine cancer therapy, Viruses 7(7):4075– 15(4):1187–1205, 2017.
4092, 2015. 182. Cicchelero L, Denies S, Vanderperren K, et al.: Immunological,
163. Sanchez D, Pelayo R, Medina LA, et al.: Newcastle disease virus: anti-angiogenic and clinical effects of intratumoral interleukin 12
potential therapeutic application for human and canine lymphoma, electrogene therapy combined with metronomic cyclophospha-
Viruses 8(1), 2015. mide in dogs with spontaneous cancer: a pilot study, Cancer Lett
164. Naik S, Galyon GD, Jenks NJ, et al.: Comparative oncology 400:205–218, 2017.
evaluation of intravenous recombinant oncolytic vesicular stoma- 183. Marks-Konczalik J, Dubois S, Losi JM, et al.: IL-2-induced activa-
titis virus therapy in spontaneous canine cancer, Mol Cancer Ther tion-induced cell death is inhibited in IL-15 transgenic mice, Proc
17(1):316–326, 2018. Natl Acad Sci U S A 97(21):11445–11450, 2000.
165. Andersen BM, Pluhar GE, Seiler CE, et al.: Vaccination for inva- 184. Zhang X, Sun S, Hwang I, et al.: Potent and selective stimulation
sive canine meningioma induces in situ production of antibodies of memory-phenotype CD8+ T cells in vivo by IL-15, Immunity
capable of antibody-dependent cell-mediated cytotoxicity, Cancer 8(5):591–599, 1998.
Res 73(10):2987–2997, 2013. 185. Antony PA, Restifo NP: CD4+CD25+ T regulatory cells, immu-
166. Gill VL, Bergman PJ, Baer KE, et al.: Use of imiquimod 5% cream notherapy of cancer, and interleukin-2, J Immunother 28(2):120–
(Aldara) in cats with multicentric squamous cell carcinoma in situ: 128, 2005.
12 cases (2002-2005), Vet Comp Oncol 6(1):55–64, 2008. 186. Waldmann TA, Lugli E, Roederer M, et al.: Safety (toxicity), phar-
167. Fogler WE, Fidler IJ: Comparative interaction of free and lipo- macokinetics, immunogenicity, and impact on elements of the
some-encapsulated nor-muramyl dipeptide or muramyl tripeptide normal immune system of recombinant human IL-15 in rhesus
phosphatidylethanolamine ( H-labelled) with human blood mono- macaques, Blood 117(18):4787–4795, 2011.
3
cytes, Int J Immunopharmacol 9(2):141–150, 1987. 187. Chou PC, Chuang TF, Jan TR, et al.: Effects of immunotherapy
168. Siegel JP, Puri RK: Interleukin-2 toxicity, J Clin Oncol 9(4):694– of IL-6 and IL-15 plasmids on transmissible venereal tumor in
704, 1991. beagles, Vet Immunol Immunopathol 130(1-2):25–34, 2009.
169. Vial T, Descotes J: Clinical toxicity of interleukin-2, Drug Saf 188. Lee SH, Shin DJ, Kim SK: Generation of recombinant canine
7(6):417–433, 1992. interleukin-15 and evaluation of its effects on the proliferation and
170. Margolin KA, Rayner AA, Hawkins MJ, et al.: Interleukin-2 and function of canine NK cells, Vet Immunol Immunopathol 165(1-
lymphokine-activated killer cell therapy of solid tumors: analysis of 2):1–13, 2015.
toxicity and management guidelines, J Clin Oncol 7(4):486–498, 189. Streck CJ, Zhang Y, Miyamoto R, et al.: Restriction of neuroblas-
1989. toma angiogenesis and growth by interferon-alpha/beta, Surgery
171. Helfand SC, Soergel SA, MacWilliams PS, et al.: Clinical and 136(2):183–189, 2004.
immunological effects of human recombinant interleukin-2 given 190. Folkman J: Successful treatment of an angiogenic disease, N Engl J
by repetitive weekly infusion to normal dogs, Cancer Immunol Med 320(18):1211–1212, 1989.
Immunother 39(2):84–92, 1994. 191. Coates A, Rallings M, Hersey P, Swanson C: Phase-II study of
172. Funk J, Schmitz G, Failing K, Burkhardt E: Natural killer (NK) recombinant alpha 2-interferon in advanced malignant melanoma,
and lymphokine-activated killer (LAK) cell functions from healthy J Interferon Res 6(1):1–4, 1986.
dogs and 29 dogs with a variety of spontaneous neoplasms, Cancer 192. Rosenthal MA, Cox K, Raghavan D, et al.: Phase II clinical
Immunol Immunother 54(1):87–92, 2005. trial of recombinant alpha-2 interferon for biopsy-proven met-
173. Khanna C, Anderson PM, Hasz DE, et al.: Interleukin-2 liposome astatic or recurrent renal carcinoma, Br J Urol 69(5):491–494,
inhalation therapy is safe and effective for dogs with spontaneous 1992.
pulmonary metastases, Cancer 79(7):1409–1421, 1997. 193. Zeidner NS, Mathiason-DuBard CK, Hoover EA: Reversal of
174. Jourdier TM, Moste C, Bonnet MC, et al.: Local immunotherapy feline leukemia virus infection by adoptive transfer of activated T
of spontaneous feline fibrosarcomas using recombinant poxviruses lymphocytes, interferon alpha, and zidovudine, Semin Vet Med Surg
expressing interleukin 2 (IL2), Gene Ther 10(26):2126–2132, (Small Anim) 10(4):256–266, 1995.
2003. 194. Penzo C, Ross M, Muirhead R, et al.: Effect of recombinant feline
175. Quintin-Colonna F, Devauchelle P, Fradelizi D, et al.: Gene ther- interferon-omega alone and in combination with chemotherapeu-
apy of spontaneous canine melanoma and feline fibrosarcoma by tic agents on putative tumour-initiating cells and daughter cells
intratumoral administration of histoincompatible cells expressing derived from canine and feline mammary tumours, Vet Comp Oncol
human interleukin-2, Gene Ther 3(12):1104–1112 7(4):222–229, 2009.
176. Jahnke A, Hirschberger J, Fischer C, et al.: Intra-tumoral gene 195. Whitley EM, Bird AC, Zucker KE, Wolfe LG: Modulation by
delivery of feIL-2, feIFN-gamma and feGM-CSF using magneto- canine interferon-gamma of major histocompatibility complex
fection as a neoadjuvant treatment option for feline fibrosarcomas: and tumor-associated antigen expression in canine mammary
a phase-I study, J Vet Med A Physiol Pathol Clin Med 54(10):599– tumor and melanoma cell lines, Anticancer Res 15(3):923–929,
606, 2007. 1995.
177. Cutrera J, Torrero M, Shiomitsu K, et al.: Intratumoral bleomycin 196. Hsiao YW, Liao KW, Chung TF, et al.: Interactions of host IL-6
and IL-12 electrochemogenetherapy for treating head and neck and IFN-gamma and cancer-derived TGF-beta1 on MHC mol-
tumors in dogs, Methods Mol Biol 423:319–325, 2008. ecule expression during tumor spontaneous regression, Cancer
178. Siddiqui F, Li CY, Zhang X, et al.: Characterization of a recom- Immunol Immunother 57(7):1091–1104, 2008.
binant adenovirus vector encoding heat-inducible feline inter- 197. Mito K, Sugiura K, Ueda K, et al.: IFN{gamma} markedly cooper-
leukin-12 for use in hyperthermia-induced gene-therapy, Int J ates with intratumoral dendritic cell vaccine in dog tumor models,
Hyperthermia 22(2):117–134, 2006. Cancer Res 70(18):7093–7101, 2010.